Highest-materiality recent filing
ENDRA Life Sciences regains Nasdaq compliance; subject to one-year monitor
Nasdaq notified ENDRA on July 8, 2026 that it regained compliance with the $2.5M Minimum Stockholders' Equity Requirement.
ENDRA Life Sciences to merge with Noble Africa (Renergen), ASP Isotopes to control combined entity
ENDRA enters merger with Noble Africa LLC; Merger Sub merges into Noble, with Noble surviving as ENDRA sub.
ENDRA Life Sciences to merge with Noble Africa (ASP Isotopes sub); raise $50M
Proposed merger of ENDRA subsidiary with Noble Africa LLC; combined entity Noble Africa Inc. to trade as NOBA.
ENDRA raises $3.8M via private placement; believes it regains Nasdaq compliance
Gross proceeds ~$3.8M from sale of 578,387 shares (or prefunded warrants) and 1,156,774 warrants at $6.57 per unit.
ENDRA receives Nasdaq delisting notice for equity falling below $2.5M minimum
Nasdaq notified ENDRA on Apr 20, 2026 that stockholders' equity of $2,260,120 as of Dec 31, 2025 fails the $2.5M minimum.
ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review
Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.
ENDRA Life Sciences cuts staff, initiates strategic alternatives review; severance costs $51K
Reduced headcount on March 19, 2026; expects ~$51K in severance charges in Q1 2026.
ENDRA Life Sciences authorized shares increased from 20M to 1B; officer exculpation rejected
Authorized common shares increased from 20M to 1B via Certificate of Amendment effective Dec 10, 2025.
ENDRA Life Sciences CTO Resigns, Enters Consulting Agreement; CFO Services Formalized
Michael Thornton resigned as CTO effective Nov 28, 2025; entered Consulting Agreement at $150/hr (first 5 hrs/week) then $100/hr.
ENDRA regains Nasdaq equity compliance after $4.9M offering; adds crypto treasury
Closed Oct 2025 private placement raising ~$4.9M gross via 744,340 shares and warrants.
ENDRA Life Sciences enters ATM equity facility for up to $1.75M through Lucid Capital Markets
Aggregate gross proceeds up to $1,750,000 from sale of common stock at-the-market.
ENDRA closes $4.9M PIPE, buys $3M in HYPE tokens, launches crypto treasury strategy
Gross proceeds of $4.9M from PIPE; potential additional $9.5M from warrant exercises.
ENDRA raises $4.9M in private placement to launch digital asset treasury strategy
Sold 744,340 shares/pre-funded warrants plus up to 1,488,680 common warrants at $6.57 per unit; $6.81 for director participant.
ENDRA raises $4.9M in private placement to launch digital asset treasury strategy managed by Arca
Gross proceeds of ~$4.9M from sale of 744,340 shares/prefunded warrants and warrants at $6.57 per unit; potential $14.4M if all warrants exercised.
ENDRA Life Sciences adopts cryptocurrency treasury strategy, forms advisory board
Retained Anchorage Digital Bank as custodian; engaged Arca Investment Management to manage crypto holdings and implement bitcoin income strategy.
ENDRA Life Sciences reports Q2 preliminary: no revenue, operating loss $1.3M
No revenue for quarter ended June 30, 2025; same as Q2 2024 with zero revenue.
ENDRA posts updated investor presentation reflecting new business strategy announced March 31, 2025
Filed under Item 7.01; presentation posted on company website without new financial or operational data.
ENDRA Life Sciences receives Nasdaq delisting notice for insufficient stockholders' equity
Stockholders' equity of $1,752,885 as of March 31, 2025, below Nasdaq's $2.5M minimum.
Net loss $1.0M in Q1 2025 vs $2.8M in Q1 2024; operating expenses down 46% to $1.5M.
ENDRA Life Sciences Q4 net loss $4.2M, cash burn cut, pivots to GLP-1 metabolic health
Q4 2024 net loss $4.2M ($1.5M in Q4 2023) includes $2.3M non-cash inventory charge; full-year net loss $11.5M.
ENDRA Life Sciences regains Nasdaq minimum bid price compliance
Received Nasdaq confirmation on Nov 21, 2024 that it meets Listing Rule 5550(a)(2).
ENDRA Life Sciences Q3 net loss $2.4M, operating expenses down 52% YoY, cash $4.7M
Net loss of $2.4M narrowed from $3.1M in Q3 2023; no revenue reported (pre-revenue stage).
ENDRA Life Sciences announces 1-for-35 reverse stock split effective Nov 7, 2024
Board approved a ratio of 1/35 for the reverse stock split authorized by stockholders on Oct 28, 2024.
ENDRA Life Sciences stockholders approve reverse stock split; board sets ratio at 1-for-35
Stockholders approved reverse stock split at Special Meeting on Oct 28, 2024 with 4,241,540 for, 2,792,189 against, 18,228 abstain.
Nasdaq Hearings Panel granted extension until November 20, 2024 to regain compliance with $1.00 minimum bid price for 10 consecutive trading days.
ENDRA Life Sciences appoints new CEO, raises $8M, reduces annual OpEx by $3.1M
New acting CEO Alexander Tokman appointed; CFO Richard Jacroux and Regulatory head Ziad Rouag join.
ENDRA Life Sciences announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance
Reverse split effective Aug 20, 2024; shares outstanding drop from ~72.4M to ~1.4M.
Francois Michelon stepped down as CEO and board member effective Aug 12, 2024; separation includes 4 months' salary and 12 months' healthcare coverage.
Senior Director of Finance Irina Pestrikova resigned Aug 7; Richard Jacroux appointed Head of Finance & principal financial officer on Aug 8.
Nasdaq notifies ENDRA Life Sciences of delisting due to bid price; company to appeal
Stock closed below $0.10 for 10 consecutive trading days ended July 12, triggering delisting under Nasdaq Rule 5810(c)(3)(A)(iii).
ENDRA Life Sciences prices $8M public offering of common stock and warrants
Gross proceeds ~$8M; offering closed June 5, 2024 with Craig-Hallum as placement agent.
ENDRA Life Sciences completes FDA pre-submission meeting for TAEUS liver device
In-person FDA pre-sub meeting held May 16, 2024, on TAEUS liver device clinical trial design for de novo submission.
Net loss of $2.8M ($0.26 per share) vs $2.9M ($0.93 per share) in Q1 2023; operating expenses $2.8M.
Expected Q1 2024 net loss of approx. $2.8M vs. $2.9M in Q1 2023; zero revenue in both quarters.
Received Nasdaq notice on May 3, 2024 for closing bid price below $1.00 for 30 consecutive trading days.
ENDRA Q4 net loss $1.5M, FDA De Novo review ongoing; Q2 meeting set
Net loss Q4 2023: $1.5M ($0.17/share) vs $3.3M ($1.04) in Q4 2022.
ENDRA Life Sciences Q3 net loss $3.1M; FDA De Novo review ongoing
Net loss $3.1M ($0.40/share) vs $3.4M ($1.09/share) in Q3 2022; operating expense $3.1M.
ENDRA files FDA De Novo for TAEUS liver system; Q2 loss $2.6M, cash $4.8M
Submitted De Novo request to FDA for TAEUS liver fat assessment system; clinical data showed 90% sensitivity and correlation r=0.78 vs MRI-PDFF.
ENDRA Life Sciences annual meeting elects directors, approves say-on-pay frequency of 1 year
All five director nominees elected: Michelon (2,024,988 for), Basenese (1,628,081), DiGiandomenico (1,976,138), Harsh (1,958,901), Tokman (2,054,532).
ENDRA Life Sciences adjourns annual meeting to Aug. 9 due to lack of quorum
Annual meeting reconvened July 25, 2023 and again adjourned for lack of quorum; new date Aug. 9, 2023 at 10:00 AM ET.
ENDRA Life Sciences adjourns 2023 annual meeting to July 25 due to lack of quorum
Annual meeting convened and adjourned July 6, 2023 because required quorum was not present.
ENDRA Life Sciences Q1 net loss $2.9M ($0.93/share); cash $2.4M; raised $4.5M in public offering
Net loss $2.9M ($0.93 per share) in Q1 2023, flat vs $2.9M ($1.33 per share) in Q1 2022.
ENDRA Life Sciences closes $4.5M public stock & warrant offering, over-allotment fully exercised
Offering of 4,312,500 shares + warrants for 2,156,250 shares at $2.41 per set (2 shares + 1 warrant).
ENDRA Life Sciences reports preliminary Q1 2023 net loss of $2.8M; no revenue
Expects no revenue for Q1 2023, consistent with Q1 2022.
ENDRA Life Sciences reports Q4 net loss $3.3M, cash $4.9M; advances TAEUS regulatory submission
Net loss Q4 2022 $3.3M ($1.04/share) vs Q4 2021 $3.1M ($1.48/share); FY2022 net loss $13.2M ($4.56/share).
ENDRA Life Sciences CCO Renaud Maloberti resigns effective Jan 13, 2023
Renaud Maloberti resigned as Chief Commercial Officer, effective January 13, 2023.
ENDRA Life Sciences extends collaborative research agreement with GE through Dec 2024
Amendment 5 extends the term of the GE collaboration to December 16, 2024.
ENDRA Life Sciences to effect 1-for-20 reverse stock split on Dec 9, 2022
Stockholders approved the 1-for-20 reverse split at a special meeting on November 29, 2022.
ENDRA Life Sciences shareholders approve reverse stock split; board sets 1-for-20 ratio
Shareholders approved amendment to authorize reverse stock split at ratio from 1-for-2 to 1-for-30.
ENDRA Q3 net loss $3.4M; cash $8.0M; 95 TAEUS scans YTD, De Novo submission near
Net loss $3.4 million ($0.05 per share) vs $2.7 million loss ($0.06) in Q3 2021.
Francois Michelon Resignation On August 12, 2024, ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) and Francois Michelon mutually agreed on Mr. Michelon’s resignation as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective August 12, 2024.
Appointment of Alexander Tokman as Acting Chief Executive Officer Effective August 13, 2024, the Board appointed Alexander Tokman as the Company’s acting Chief Executive Officer and Chairman.
On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance.
On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.
On December 21, 2022, Renaud Maloberti notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of his resignation as the Company’s Chief Commercial Officer, effective January 13, 2023.
Max materiality 1.00 · Median 0.60 · Most common event other_material